The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer
Open accessAbstract
Progress in ovarian cancer treatment lags behind other tumor types. With diagnosis usually at an advanced stage, there is a high demand for reliable prognostic biomarkers capable of the selection of effective chemo- and targeted therapies. Our goal was to establish a large-scale transcriptomic database and use it to uncover and rank survival-associated genes. Ovarian cancer cohorts with transcriptome-level gene expression data and clinical follow-up were identified from public repositories. All samples were normalized and entered into an integrated database. Cox univariate survival analysis was performed for all genes and was followed by multivariate analysis for selected genes involving clinical and pathological variables. False discovery rate was computed for multiple hypothesis testing and a 1% cutoff was used to determine statistical significance. The complete integrated database comprises 1816 samples from 17 datasets. Altogether, 2468 genes were correlated to progression-free survival (PFS), and 704 genes were correlated with overall survival (OS). The most significant genes were WBP1L, ASAP3, CNNM2, and NCAPH2 for progression-free survival and CSE1L, NUAK1, ALPK2, and SHKBP1 for overall survival. Genes significant for PFS were also preferentially significant for predicting OS as well. All data including HR and p values as well as the used cutoff values for all genes for both PFS and OS are provided to enable the ranking of future biomarker candidates across all genes. Our results help to prioritize genes and to neglect those which are most likely to fail in studies aiming to establish new clinically useful biomarkers and therapeutic targets in serous ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
xCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Ovarian Cancer: An Integrated Review
Stewart, C., Ralyea, C., & Lockwood, S. (2019) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2019.02.001 · Cited by 1,090
Bartha, Á., & Győrffy, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052622 · Cited by 1,060
Self-citationDisis, M. L., Taylor, M. H., Kelly, K., Beck, J. T., Gordon, M., Moore, K. M., Patel, M. R., Chaves, J., Park, H., Mita, A. C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6258 · Cited by 437
Kurian, A. W., Ward, K. C., Howlader, N., Deapen, D., Hamilton, A. S., Mariotto, A., Miller, D., Penberthy, L. S., & Katz, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01854 · Cited by 387
Jetset: selecting the optimal microarray probe set to represent a gene
Li, Q., Birkbak, N. J., Gyorffy, B., Szallasi, Z., & Eklund, A. C. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-474 · Cited by 324
Chemotherapy Resistance in Advanced Ovarian Cancer Patients
Pokhriyal, R., Hariprasad, R., Kumar, L., & Hariprasad, G. (2019) · Biomarkers in Cancer · doi:10.1177/1179299x19860815 · Cited by 283
Cited by
Győrffy, B. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100625 · Cited by 464
Self-citationDe novo and salvage purine synthesis pathways across tissues and tumors
Tran, D. H., Kim, D., Kesavan, R., Brown, H., Dey, T., Soflaee, M. H., Vu, H. S., Tasdogan, A., Guo, J., Bezwada, D., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.011 · Cited by 213
Brito, D. M. S., Lima, O. G., Mesquita, F. P., da Silva, E. L., de Moraes, M. E. A., Burbano, R. M. R., Montenegro, R. C., & Souza, P. F. N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092303 · Cited by 6
Metadata
- Authors
- Győrffy, B.
- Venue
- GeroScience
- Published
- 2023-03-01
- Volume
- 45
- Issue
- 3
- Pages
- 1889-1898
- ISSN
- 2152-4041 (ISSN-L)
- 2509-2723
- OpenAlex
- W4322718934
- Cited by
- 381
- References
- 30
- FWCI
- 76.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. https://app.cochat.ai/papers/10.1007/s11357-023-00742-4
- The paper
- Győrffy, B. (2023). Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. GeroScience. https://doi.org/10.1007/s11357-023-00742-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.